Your session is about to expire
← Back to Search
Gracie Diet for Acid Reflux
N/A
Recruiting
Led By Pankaj Pasricha, MD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Use of one of the following PPI medications: omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole or dexlansoprazole. And/or use of one of the following H2 blockers medications as well: famotidine, cimetidine, ranitidine or nizatidine
Age 18 years or older at registration
Must not have
A prior surgery of the upper gastrointestinal tract
Age < than 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 2 and week 4
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing the Gracie Diet, which involves specific food combinations and meal spacing, to help people with GERD who don't get better with usual medications. The diet aims to improve digestion and reduce symptoms by preventing bad chemical reactions in the stomach.
Who is the study for?
This trial is for adults over 18 with ongoing GERD symptoms like heartburn and regurgitation, who are already taking PPIs or H2 blockers. It's not for those who can't speak English, have had upper GI surgery, are pregnant/nursing, or have other conditions that might affect their participation.
What is being tested?
The Gracie Diet is being tested as a potential alternative to improve GERD symptoms in patients unresponsive to standard doses of PPIs and/or H2 receptor antagonists. The diet focuses on food combinations to prevent digestive issues like fermentation and acidity.
What are the potential side effects?
While the study doesn't list specific side effects of the Gracie Diet, changes in diet may lead to initial discomfort such as bloating or changes in bowel habits as the body adjusts to new eating patterns.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am currently taking a PPI or H2 blocker medication.
Select...
I am 18 years old or older.
Select...
I experience symptoms like heartburn, chest pain, or difficulty swallowing due to GERD.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had surgery on my upper stomach area before.
Select...
I am under 18 years old.
Select...
I am unable to communicate in English.
Select...
I have difficulty swallowing that could lead to choking.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, week 2 and week 4
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 2 and week 4
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in GERD medication
Change in Patient Reported Outcomes Measurement Information System (PROMIS) scale score
Change in University of California Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT 2.0) score
+3 moreSecondary study objectives
Change in Body Mass Index (BMI)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Gracie DietExperimental Treatment1 Intervention
Patients will have a nutritional consultation and will follow the Gracie diet for a month.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Acid Reflux include dietary modifications, proton pump inhibitors (PPIs), and H2 receptor antagonists (H2RAs). Dietary modifications, such as those proposed by the Gracie Diet, aim to improve digestion and reduce GERD symptoms by promoting the consumption of proper food combinations and avoiding foods that trigger acid production and fermentation.
This approach helps prevent the chemical reactions in the digestive process that can lead to heartburn and regurgitation. PPIs work by potently inhibiting gastric acid secretion, thereby reducing acid reflux and healing the esophagus.
H2RAs decrease gastric acid secretion by blocking histamine H2 receptors on gastric parietal cells. These treatments are crucial for Acid Reflux patients as they help manage symptoms, improve quality of life, and prevent complications associated with chronic acid exposure.
Find a Location
Who is running the clinical trial?
Johns Hopkins UniversityLead Sponsor
2,326 Previous Clinical Trials
14,874,699 Total Patients Enrolled
Pankaj Pasricha, MDPrincipal InvestigatorJohns Hopkins University
6 Previous Clinical Trials
292 Total Patients Enrolled
Robert Bulat, MDPrincipal InvestigatorJohns Hopkins University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am currently taking a PPI or H2 blocker medication.I have had surgery on my upper stomach area before.I am currently taking a PPI or H2 blocker medication.My symptoms are not due to GI obstruction, Barrett's esophagus, or esophageal cancer.I am under 18 years old.I am unable to communicate in English.I am 18 years old or older.I experience symptoms like heartburn, chest pain, or difficulty swallowing due to GERD.I have difficulty swallowing that could lead to choking.I experience ongoing symptoms like heartburn, chest pain, or difficulty swallowing due to GERD.I am 18 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: Gracie Diet
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger